Expanded use of rituximab in the management of non-Hodgkin lymphoma

References

• ChanJKThe new World Health Organization classification of lymphomas: the past, the present and the futureHematol Oncol200119412915011754390
   PubMed Web of Science ®Google Scholar
• FisherRIGaynorERDahlbergSComparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphomaN Engl J Med199332814100210067680764
   PubMed Web of Science ®Google Scholar
• GallagherCJGregoryWMJonesAEFollicular lymphoma: prognostic factors for response and survivalJ Clin Oncol1986410147014803531422
   PubMed Web of Science ®Google Scholar
• ArdeshnaKMSmithPNortonALong-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trialLancet16 2003362938351652212932382
   PubMed Web of Science ®Google Scholar
• HorningSJNatural history of and therapy for the indolent non-Hodgkin’s lymphomasSemin Oncol1993205 Suppl 575888211209
   PubMed Web of Science ®Google Scholar
• ArmitageJOWeisenburgerDDNew approach to classifying non-Hodgkin’s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin’s Lymphoma Classification ProjectJ Clin Oncol1998168278027959704731
   PubMed Web of Science ®Google Scholar
• StashenkoPNadlerLMHardyRSchlossmanSFCharacterization of a human B lymphocyte-specific antigenJ Immunol19801254167816856157744
   PubMed Web of Science ®Google Scholar
• ReffMECarnerKChambersKSDepletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20Blood19948324354457506951
   PubMed Web of Science ®Google Scholar
• FliegerDRenothSBeierISauerbruchTSchmidt-WolfIMechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell linesCell Immunol20002041556311006018
   PubMed Web of Science ®Google Scholar
• DemidemALamTAlasSHariharanKHannaNBonavidaBChimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugsCancer Biother Radiopharm199712317718610851464
   PubMed Web of Science ®Google Scholar
• PressOWAppelbaumFLedbetterJAMonoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomasBlood19876925845913492224
   PubMed Web of Science ®Google Scholar
• MaloneyDGGrillo-LopezAJBodkinDJIDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin’s lymphomaJ Clin Oncol19971510326632749336364
   PubMed Web of Science ®Google Scholar
• MaloneyDGGrillo-LopezAJWhiteCAIDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphomaBlood1997906218821959310469
   PubMed Web of Science ®Google Scholar
• McLaughlinPGrillo-LopezAJLinkBKRituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment programJ Clin Oncol1998168282528339704735
   PubMed Web of Science ®Google Scholar
• BerinsteinNLGrillo-LopezAJWhiteCAAssociation of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphomaAnn Oncol19989999510019818074
   PubMed Web of Science ®Google Scholar
• CoiffierBLepretreSPedersenLMSafety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1–2 studyBlood200811131094110018003886
   PubMed Web of Science ®Google Scholar
• GoldenbergDMRossiEASteinRProperties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibodyBlood200911351062107018941114
   PubMed Web of Science ®Google Scholar
• HagenbeekAGadebergOJohnsonPFirst clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trialBlood2008111125486549518390837
   PubMed Web of Science ®Google Scholar
• CzuczmanMSGrillo-LopezAJWhiteCATreatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapyJ Clin Oncol199917126827610458242
   PubMed Web of Science ®Google Scholar
• HiddemannWKnebaMDreylingMFrontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study GroupBlood2005106123725373216123223
   PubMed Web of Science ®Google Scholar
• SallesGMounierNde GuibertSRituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 studyBlood2008112134824483118799723
   PubMed Web of Science ®Google Scholar
• MarcusRImrieKSolal-CelignyPPhase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphomaJ Clin Oncol200826284579458618662969
   PubMed Web of Science ®Google Scholar
• SchulzHBohliusJSkoetzNChemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin’s lymphomaCochrane Database Syst Rev20074CD00380517943799
   PubMed Web of Science ®Google Scholar
• RummelMJAl-BatranSEKimSZBendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin’s lymphomaJ Clin Oncol200523153383338915908650
   PubMed Web of Science ®Google Scholar
• RummelMJvon GruenhagenUNiederleNBendamustine plus Rituximab versus CHOP plus Rituximab in the first-line treatment of patients with indolent and mantle cell lymphomas - first interim results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany)Blood (ASH Annual Meeting abstracts)200711011Abstract 385.
   Google Scholar
• van OersMHKlasaRMarcusRERituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trialBlood2006108103295330116873669
   PubMed Web of Science ®Google Scholar
• ForstpointnerRUnterhaltMDreylingMMaintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)Blood2006108134003400816946304
   PubMed Web of Science ®Google Scholar
• HainsworthJDLitchySBurrisHA3rdRituximab as first-line and maintenance therapy for patients with indolent non-hodgkin’s lymphomaJ Clin Oncol200220204261426712377971
   PubMed Web of Science ®Google Scholar
• LenzGDreylingMHosterEImmunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)J Clin Oncol20052391984199215668467
   PubMed Web of Science ®Google Scholar
• SchulzHKleinSKRehwaldUPhase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemiaBlood200210093115312012384407
   PubMed Web of Science ®Google Scholar
• RehwaldUSchulzHReiserMTreatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study GroupBlood2003101242042412509381
   PubMed Web of Science ®Google Scholar
• SchulzHRehwaldUMorschhauserFRituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG)Blood2008111110911117938252
   PubMed Web of Science ®Google Scholar
• TillyHDreylingMDiffuse large B-cell non-Hodgkin’s lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-upAnn Oncol200819Suppl 2ii67ii6918456774
   PubMed Web of Science ®Google Scholar
• VoseJMLinkBKGrossbardMLPhase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin’s lymphomaJ Clin Oncol200119238939711208830
   PubMed Web of Science ®Google Scholar
• PfreundschuhMTrumperLOsterborgACHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) GroupLancet Oncol20067537939116648042
   PubMed Web of Science ®Google Scholar
• CoiffierBLepageEBriereJCHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphomaN Engl J Med2002346423524211807147
   PubMed Web of Science ®Google Scholar
• PfreundschuhMTrumperLKloessMTwo-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHLBlood2004104363464115016643
   PubMed Web of Science ®Google Scholar
• PfreundschuhMSchubertJZiepertMSix versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)Lancet Oncol20089210511618226581
   PubMed Web of Science ®Google Scholar
• HabermannTMWellerEAMorrisonVARituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphomaJ Clin Oncol200624193121312716754935
   PubMed Web of Science ®Google Scholar
• VellengaEvan PuttenWLvan ‘t VeerMBRituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trialBlood2008111253754317971487
   PubMed Web of Science ®Google Scholar
• KimbyETolerability and safety of rituximab (MabThera)Cancer Treat Rev200531645647316054760
   PubMed Web of Science ®Google Scholar
• WagnerSAMehtaACLaberDARituximab-induced interstitial lung diseaseAm J Hematol2007821091691917597477
   PubMed Web of Science ®Google Scholar
• LiuXHongXNGuYJWangBYLuoZGCaoJInterstitial pneumonitis during rituximab-containing chemotherapy for non-Hodgkin lymphomaLeuk Lymphoma20084991778178318798110
   PubMed Web of Science ®Google Scholar
• SchulzHBohliusJFTrelleSImmunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysisJ Natl Cancer Inst200799970671417470738
   PubMed Web of Science ®Google Scholar
• Witzens-HarigMReizMHeissCQuality of life during maintenance therapy with the anti-CD20 antibody rituximab in patients with B cell non-Hodgkin’s lymphoma: results of a prospective randomized controlled trialAnn Hematol2008
   Web of Science ®Google Scholar
• ForstpointnerRDreylingMReppRThe addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study GroupBlood2004104103064307115284112
   PubMed Web of Science ®Google Scholar
• SebbanCBricePDelarueRImpact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA studyJ Clin Oncol200826213614362018559872
   PubMed Web of Science ®Google Scholar
• HeroldMPasoldRSrockSNeserSNiederwieserDNeubauerAResults of a prospective randomised open label phase iii study comparing rituximab plus mitoxantrone, chlorambucile, prednisolone chemotherapy (R-MCP) versus MCP alone in untreated advanced indolent non-Hodgkin’s lymphoma (NHL) and mantle-cell-lymphoma (MCL). ASH Annual Meeting Abstracts2004104584
   Google Scholar
• HeroldMHaasASrockSRituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology StudyJ Clin Oncol200725151986199217420513
   PubMed Web of Science ®Google Scholar
• MarcusRImrieKBelchACunninghamDFloresECatalanoJCVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphomaBlood20051051417142315494430
   PubMed Web of Science ®Google Scholar
• Rivas-VeraSBaezESobrevilla-CalvoPBaltazarSTrippFVelaJIs first line single agent rituximab the best treatment for indolent non-Hodgkin’s lymphoma? Update of a multicentric study comparing rituximab vs CNOP vs rituximab plus CNOP. ASH Annual Meeting Abstracts20051062431
   Google Scholar